THERAPHARM GMBH has a total of 19 patent applications. It increased the IP activity by 500.0%. Its first patent ever was published in 2002. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are ZIOPHARM ONCOLOGY INC, INSTITUTO NAC DE INVESTIGACIONES NUCLEARES and OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU WDS FARMA.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | United States | 3 | |
#4 | Australia | 2 | |
#5 | Canada | 2 | |
#6 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Special acyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Orchard Kim | 10 |
#2 | Bosslet Klaus | 10 |
#3 | Droz Ladislav | 8 |
#4 | Benes Ivan | 7 |
#5 | Sramek Martin | 6 |
#6 | Cihelnik Simon | 6 |
#7 | Ladislav Droz | 1 |
#8 | Ivan Benes | 1 |
#9 | Klaus Bosslet | 1 |
#10 | Hermann Petr | 1 |
Publication | Filing date | Title |
---|---|---|
EP3351271A1 | Radioimmunoconjugate for use in treating bone marrow associated diseases | |
WO2011144744A1 | Targeted radioactive compound for human cd66 for the treatment of disorders | |
AU2006319361A1 | Radioimmunoconjugate for human CD66 for the treatment of multiple myeloma | |
WO2007028639A1 | Method for the synthesis of pentapendant enantiomer-pure chelators and process for therapeutically active bio-conjugates preparation by a covalent binding of thereof | |
EP1812453A1 | Method of preparing or synthesizing polyazamacrocycle derivatives | |
WO03008394A1 | Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |